Last reviewed · How we verify
Lucentis every 4 weeks
Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina.
Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.
At a glance
| Generic name | Lucentis every 4 weeks |
|---|---|
| Sponsor | Retinal Consultants of Arizona |
| Drug class | VEGF-A inhibitor (monoclonal antibody fragment) |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds and neutralizes all active forms of VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF-A signaling, it prevents endothelial cell proliferation and reduces retinal edema, thereby stabilizing or improving vision in conditions characterized by abnormal retinal vasculature.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Macular edema following retinal vein occlusion
- Diabetic macular edema
- Diabetic retinopathy
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
- Retinal detachment
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (PHASE3)
- Extension Study for the Port Delivery System With Ranibizumab (Portal) (PHASE3)
- A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PHASE3)
- A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) (PHASE3)
- A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss (PHASE3)
- Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration (PHASE3)
- Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) (PHASE3)
- Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lucentis every 4 weeks CI brief — competitive landscape report
- Lucentis every 4 weeks updates RSS · CI watch RSS
- Retinal Consultants of Arizona portfolio CI